임상시험 제3자 물류 시장 : 시장 규모, 점유율, 동향 분석(서비스별, 상별, 치료 영역별, 최종 용도별, 지역별), 부문별 예측(2026-2033년)

Clinical Trial Third Party Logistics Market Summary

The global clinical trial third party logistics market size was estimated at USD 3.13 billion in 2025 and is projected to reach USD 5.93 billion by 2033, growing at a CAGR of 8.51% from 2026 to 2033. The growing globalization of clinical research, rising number of ongoing and planned clinical trials, and increasing R&D spending by pharmaceutical and biopharmaceutical companies are key factors expected to support market expansion.

In addition, ongoing advancements in supply chain technologies are enhancing operational efficiency, transparency, and reliability across clinical trial logistics. The increasing complexity of study designs, including multi-regional, decentralized, and advanced therapy trials, is further driving the adoption of digital tracking, real-time monitoring, and data-driven logistics solutions to enable faster, more compliant, and cost-effective clinical trial execution.

The clinical trial 3PL market is experiencing strong growth due to the rising adoption of precision medicine, biologics, and decentralized clinical trial models, which have significantly increased the need for specialized outsourced logistics services. Advanced therapies require stringent temperature control, customized packaging, secure transportation, and real-time monitoring to maintain product integrity and regulatory compliance across global trial sites. As a result, pharmaceutical and biotechnology companies are increasingly relying on third-party logistics providers to manage complex distribution networks, cold chain requirements, and global site coordination, thereby supporting market expansion.

In addition, the growing complexity of multi-regional trials, expansion into emerging markets, and increasing regulatory scrutiny are accelerating the shift toward outsourced logistics models. Sponsors are focusing on core drug development activities while leveraging the expertise of 3PL providers in areas such as inventory management, risk mitigation, demand forecasting, and last-mile delivery. The integration of digital tracking platforms, IoT-enabled temperature monitoring, and just-in-time supply strategies is further enhancing operational efficiency and visibility across the clinical trial logistics ecosystem. Strategic partnerships and service expansion initiatives are also enabling logistics providers to broaden their global reach and strengthen service portfolios.

Furthermore, increasing R&D investments and the expanding pipeline of biologics, cell and gene therapies, and specialty injectables are expected to drive sustained demand for outsourced clinical trial logistics. Pharmaceutical and biotechnology companies are investing in global trial expansion and patient-centric approaches, which require flexible, scalable, and compliant logistics networks. Leading providers such as DHL and UPS Healthcare continue to expand temperature-controlled infrastructure, digital capabilities, and regional distribution hubs to address evolving sponsor requirements, reinforcing the long-term growth outlook of the clinical trial third party logistics industry.

Global Clinical Trial Third Party Logistics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country level and provides an analysis on the latest trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the clinical trial third party logistics market report based on service, phase, therapeutic area, end use, and region:

• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Logistics & Distribution
• Storage & Retention
• Packaging, Labeling, and Blinding
• Comparator Sourcing
• Other Services
• Phase Outlook (Revenue, USD Million, 2021 - 2033)
• Phase I
• Phase II
• Phase III
• Phase IV
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Cardiovascular Diseases
• Respiratory Diseases
• CNS and Mental Disorders
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations (CROs)
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Regional Scope
  • 1.1.2. Estimates and Forecast Timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Purchased Database
  • 1.3.3. GVR's Internal Database
  • 1.3.4. Secondary Sources
  • 1.3.5. Primary Research
• 1.4. Information or Data Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation & Validation
  • 1.5.1. Region Wise Market: Base Estimates
  • 1.5.2. Global Market: CAGR Calculation
• 1.6. Model Details
  • 1.6.1. Commodity Flow Analysis (Model 1)
  • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
  • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
  • 1.6.4. Bottom-Up Approach (Model 4)
• 1.7. List of Secondary Sources
• 1.8. List of Abbreviations
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
    • 3.3.1.1. Technological Advancements in Supply Chain
    • 3.3.1.2. Increasing R&D Investment by Pharmaceutical and Biopharmaceutical Firms
    • 3.3.1.3. Increasing Demand For Outsourcing Services Across The Developing Economies
    • 3.3.1.4. Expansion of Clinical Trial Sites
  • 3.3.2. Market Restraint Analysis
    • 3.3.2.1. Stringent Regulation Pertaining to Logistics
    • 3.3.2.2. Counterfeiting of Drugs
• 3.4. Technological Advancements
  • 3.4.1. Integration of AI and Digital Technologies
• 3.5. Pricing Model Analysis
• 3.6. Clinical Trials Volume Analysis, 2024
  • 3.6.1. Total Number of Clinical Trials, by Region (2024)
  • 3.6.2. Total Number of Clinical Trials, by Phase (2024)
  • 3.6.3. Total Number of Clinical Trials, by Study Design (2024)
  • 3.6.4. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Forces Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Clinical Trial Third Party Logistics Market: Service Estimates & Trend Analysis

• 4.1. Clinical Trial Third Party Logistics Market, By Service: Segment Dashboard
• 4.2. Clinical Trial Third Party Logistics Market, By Service: Movement Analysis
• 4.3. Clinical Trial Third Party Logistics Market Estimates & Forecasts, By Service, 2021 - 2033
• 4.4. Logistics & Distribution
  • 4.4.1. Logistics & Distribution Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
• 4.5. Storage & Retention
  • 4.5.1. Storage & Retention Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
• 4.6. Packaging, Labeling, and Blinding
  • 4.6.1. Packaging, Labeling, and Blinding Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
• 4.7. Comparator Sourcing
  • 4.7.1. Comparator Sourcing Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
• 4.8. Other Services
  • 4.8.1. Other Services Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)

Chapter 5. Clinical Trial Third Party Logistics Market: Phase Estimates & Trend Analysis

• 5.1. Clinical Trial Third Party Logistics Market, By Phase: Segment Dashboard
• 5.2. Clinical Trial Third Party Logistics Market, By Phase: Movement Analysis
• 5.3. Clinical Trial Third Party Logistics Market Estimates & Forecasts, By Phase, 2021 - 2033
• 5.4. Phase I
  • 5.4.1. Phase I Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
• 5.5. Phase II
  • 5.5.1. Phase II Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
• 5.6. Phase III
  • 5.6.1. Phase III Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
• 5.7. Phase IV
  • 5.7.1. Phase IV Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)

Chapter 6. Clinical Trial Third Party Logistics Market: Therapeutic Area Estimates & Trend Analysis

• 6.1. Clinical Trial Third Party Logistics Market, By Therapeutic Area: Segment Dashboard
• 6.2. Clinical Trial Third Party Logistics Market, By Therapeutic Area: Movement Analysis
• 6.3. Clinical Trial Third Party Logistics Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033
• 6.4. Oncology
  • 6.4.1. Oncology Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
• 6.5. Cardiovascular Diseases
  • 6.5.1. Cardiovascular Diseases Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
• 6.6. Respiratory Diseases
  • 6.6.1. Respiratory Diseases Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
• 6.7. CNS and Mental Disorders
  • 6.7.1. CNS and Mental Disorders Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)

Chapter 7. Clinical Trial Third Party Logistics Market: End Use Estimates & Trend Analysis

• 7.1. Clinical Trial Third Party Logistics Market, By End Use: Segment Dashboard
• 7.2. Clinical Trial Third Party Logistics Market, By End Use: Movement Analysis
• 7.3. Clinical Trial Third Party Logistics Market Estimates & Forecasts, By End Use, 2021 - 2033
• 7.4. Pharmaceutical and Biotechnology Companies
  • 7.4.1. Pharmaceuticals Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
• 7.5. Contract Research Organizations (CROs)
  • 7.5.1. Biologicals Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
• 7.6. Others
  • 7.6.1. Medical Device Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)

Chapter 8. Clinical Trial Third Party Logistics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Regional Market Snapshot
• 8.4. North America
  • 8.4.1. North America Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. U.S. Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Canada Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Mexico Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. UK Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Germany Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. France Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Italy Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Spain Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Denmark Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Sweden Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Norway Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Japan Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. China Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. India Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Australia Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. South Korea Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Thailand Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Brazil Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Argentina Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.7.4. Colombia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Colombia Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. South Africa Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Saudi Arabia Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. UAE Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Kuwait Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.8.6. Oman
    • 8.8.6.1. Key Country Dynamics
    • 8.8.6.2. Competitive Scenario
    • 8.8.6.3. Regulatory Framework
    • 8.8.6.4. Oman Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)
  • 8.8.7. Qatar
    • 8.8.7.1. Key Country Dynamics
    • 8.8.7.2. Competitive Scenario
    • 8.8.7.3. Regulatory Framework
    • 8.8.7.4. Qatar Clinical Trial Third Party Logistics Market Estimates and Segment Forecasts, 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Company Profiles
  • 9.2.1. Thermo Fisher Scientific Inc.
    • 9.2.1.1. Company Overview
    • 9.2.1.2. Financial Performance
    • 9.2.1.3. Service Benchmarking
    • 9.2.1.4. Strategic Initiatives
  • 9.2.2. UPS Healthcare
    • 9.2.2.1. Company Overview
    • 9.2.2.2. Financial Performance
    • 9.2.2.3. Service Benchmarking
    • 9.2.2.4. Strategic Initiatives
  • 9.2.3. Piramal Pharma Solutions
    • 9.2.3.1. Company Overview
    • 9.2.3.2. Financial Performance
    • 9.2.3.3. Service Benchmarking
    • 9.2.3.4. Strategic Initiatives
  • 9.2.4. DHL
    • 9.2.4.1. Company Overview
    • 9.2.4.2. Financial Performance
    • 9.2.4.3. Service Benchmarking
    • 9.2.4.4. Strategic Initiatives
  • 9.2.5. Parexel International
    • 9.2.5.1. Company Overview
    • 9.2.5.2. Financial Performance
    • 9.2.5.3. Service Benchmarking
    • 9.2.5.4. Strategic Initiatives
  • 9.2.6. Almac Group
    • 9.2.6.1. Company Overview
    • 9.2.6.2. Financial Performance
    • 9.2.6.3. Service Benchmarking
    • 9.2.6.4. Strategic Initiatives
  • 9.2.7. Movianto
    • 9.2.7.1. Company Overview
    • 9.2.7.2. Financial Performance
    • 9.2.7.3. Service Benchmarking
    • 9.2.7.4. Strategic Initiatives
  • 9.2.8. UDG Healthcare
    • 9.2.8.1. Company Overview
    • 9.2.8.2. Financial Performance
    • 9.2.8.3. Service Benchmarking
    • 9.2.8.4. Strategic Initiatives
  • 9.2.9. FedEx
    • 9.2.9.1. Company Overview
    • 9.2.9.2. Financial Performance
    • 9.2.9.3. Service Benchmarking
    • 9.2.9.4. Strategic Initiatives
  • 9.2.10. Catalent, Inc.
    • 9.2.10.1. Company Overview
    • 9.2.10.2. Financial Performance
    • 9.2.10.3. Service Benchmarking
    • 9.2.10.4. Strategic Initiatives